About Vycellix

About Vycellix

Headquartered in Florida with scientific operations in Sweden, Vycellix has developed a broad suite of cell therapy engineering solutions with the mission to deliver superior outcomes for patients through the delivery of highly innovative allogeneic medicines that eliminate the risk of immune rejection.

Leveraging the Company’s transformational single-step CD45 engager allogeneic platform (VY-UC) Vycellix is engineering immune-privileged, donor-derived effector cells, obviating the need for immune-suppressive drugs and redefining the paradigm for “off-the-shelf” cell therapy with optimized, functional persistence. Vycellix is preparing to launch a Phase 1 clinical trial for VNK-101, its highly differentiated, allogeneic NK cell therapy (powered by VY-UC) for the treatment of multiple myeloma blood cancer.

Beyond VY-UC, the Company’s cell engineering platforms represent ideal solutions to enhance and optimize multi-antigen engagement (VY-GAGE), gene delivery (VY-OZ), cell expansion (VY-M), and cell potency (VY-X).

Vycellix has achieved key milestones on pathway to:

  • Redefine the paradigm for transplant medicine, enabling the delivery of any donor cell to any patient while eliminating risk of immune rejection (VY-UC)
  • Achieve first-in-human, proof-of-concept for off-the-shelf NK cell cancer therapy (VNK-101)
  • Establish new leading class of multi-antigen engagers with precision tumor-activated delivery, avoiding “on-target, off-tumor” effect (VY-GAGE)

Karolinska Institutet & NextGenNK:
Vycellix’s platforms were all discovered by scientists at the world-renowned Karolinska Institutet (KI), Sweden.  The Company is also a collaborative partner in NextGenNK.  Based at KI, NextGenNK is the Swedish Innovation Agency’s Competence Center for the delivery of next-generation NK cell-based cancer immunotherapies.  KI is recognized for its Nobel Assembly, which annually awards the Nobel Prize in Physiology or Medicine.

Visit NextGenNK: https://ki.se/en/research/research-areas-centres-and-networks/research-centres/nextgennk